If you’re keeping score in the liquid biopsy race
Guardant Health, owner of one last year's best-performing IPOs, is launching a huge trial it hopes will prove that it can diagnose colon cancer with a blood test.
As STAT’s Matthew Herper reports, Guardant’s 10,000-patient study will determine how well the company’s test compares with colonoscopy when it comes to cancer or pre-cancerous polyps. If it’s positive, Guardant will make its case to the FDA.
The news comes as a host of companies jostle to develop blood tests that might detect cancer at its earliest — and most treatable — stages. The multibillion-dollar allure of that idea has attracted companies including Freenome, Thrive, and a unicorn unsubtly named Grail.
Read more.
As STAT’s Matthew Herper reports, Guardant’s 10,000-patient study will determine how well the company’s test compares with colonoscopy when it comes to cancer or pre-cancerous polyps. If it’s positive, Guardant will make its case to the FDA.
The news comes as a host of companies jostle to develop blood tests that might detect cancer at its earliest — and most treatable — stages. The multibillion-dollar allure of that idea has attracted companies including Freenome, Thrive, and a unicorn unsubtly named Grail.
Read more.
.png)
No hay comentarios:
Publicar un comentario